As a scientist and medical oncologist, Dr Jenny Lee has dedicated her career to lessening the burden of cancer by caring for patients and finding more effective treatments. Here, she discusses her latest role as Co-Director of the Cancer Biomarker Centre at Chris O’Brien Lifehouse.
Biomarkers are like clues in the body that help us understand how a cancer might behave and how it might respond to treatment. By studying these clues, Jenny and her team can develop better and more personalised treatments for people with cancer.
“Our centre tests if biomarkers are reliable and accurate for use in treatments,” says Jenny. “This stage of research is often difficult to execute due to funding challenges, but it’s where our centre will make the biggest impact thanks to donor contributions.”
“One project I’m particularly excited about is focused on prostate cancer, led by my colleague, Professor Lisa Horvath. Her team discovered a biomarker called PCPro that helps identify patients whose cancer might resist treatment due to specific patterns in their blood.”
“We are now developing a clinical trial that uses a simple blood test to find patients with the PCPro biomarker and enhance their treatment with a new drug targeting these patterns. This research could lead to better treatment options for prostate cancer patients.”
As a supporter of Chris O’Brien Lifehouse, you are helping fund the vital infrastructure and systems needed for our research and for translating our discoveries into real-world treatments. Your support is already making a difference in the lives of people with cancer and will continue to do so in the future – thank you so much!
Biomarkers are like clues in the body that help us understand how a cancer might behave and how it might respond to treatment. By studying these clues, Jenny and her team can develop better and more personalised treatments for people with cancer.
“Our centre tests if biomarkers are reliable and accurate for use in treatments,” says Jenny. “This stage of research is often difficult to execute due to funding challenges, but it’s where our centre will make the biggest impact thanks to donor contributions.”
“One project I’m particularly excited about is focused on prostate cancer, led by my colleague, Professor Lisa Horvath. Her team discovered a biomarker called PCPro that helps identify patients whose cancer might resist treatment due to specific patterns in their blood.”
“We are now developing a clinical trial that uses a simple blood test to find patients with the PCPro biomarker and enhance their treatment with a new drug targeting these patterns. This research could lead to better treatment options for prostate cancer patients.”
As a supporter of Chris O’Brien Lifehouse, you are helping fund the vital infrastructure and systems needed for our research and for translating our discoveries into real-world treatments. Your support is already making a difference in the lives of people with cancer and will continue to do so in the future – thank you so much!
